Maybe this is to simplistic of thinking or I am missing all of the facts if so I apologize ahead of time. I think we have been led to believe that until recently RNA was going to potentially beat SRPT to market because RNA was ahead of the game in clinical trials. Which begs the questions if I am the CEO of SRPT and I had any idea or thought that my drug faced potential delays or rejection by FDA or clinical trials studies indicated any potential issues I do not believe I would be way out in front of the DMD public. SRPT is basically gathering a data base for potential patients now. Was RNA doing any of that?
All you guys that were bad mouthing the #$%$ outta ppmd need to take a deep breath this is good for the kids with dmd and good for srpt shareholders, sometimes things are not as they seem cause we don't have all the info this is an example.
I disagree. Sorry, but this new project should be listed on the front page. Further, PPMD claims on the site " Because of this, PPMD monitors and posts all current Duchenne research and community updates"..............................YET, you have to go all the way back to July, to find the first SRPT mention regarding the FDA inviting them to file their NDA. THAT is the only SRPT mention in the "news" section. The front page literally mentions nothing about the new project with SRPT.
SRPT is the only drug within striking distance of actually helping these sick kids, and yet, PPMD has tons of stuff about everything else. Say what you want Thigrlsk, but I think she is dropping the ball in a big way, and ignoring PPMD's mission statement. At the very least, PPMD does not appear to be very excited about this new testing program, because it's not as important apparently, as reviewing the GSK failure, and other far less important stuff, than making boys better.
And yet..................there is no mention of this project ON THE FRONT PAGE of their website. Apparently, this new project is not important enough to bump something like "RNA p3 fails to meet primary endpoint" off of the first page. Gimme a break!